Study protocol of a randomised, double-blind, placebo-controlled, two-arm parallel-group, multi-centre phase 3 pivotal trial to investigate the efficacy and safety of recombinant human alkaline phosphatase for treatment of patients with sepsis-associated acute kidney injury
Peter Pickkers(Radboud University Nijmegen), Anne Louise Kjølbye(Ferring Pharmaceuticals (Denmark)), Rinaldo Bellomo(The University of Melbourne), Ville Pettilä(University of Helsinki), Alexander Zarbock(University Hospital Münster), John A. Kellum(University of Pittsburgh), Kent Doi(University of Tokyo Hospital), Michael Joannidis(Innsbruck Medical University), Ricard Ferrer(Universitat Autònoma de Barcelona), Paul J. Young(Wellington Hospital), Sharon Richards(Amgen (United Kingdom)), Derek C. Angus(University of Pittsburgh), Pierre‐François Laterre(Cliniques Universitaires Saint-Luc), Morten H. Bestle(University of Copenhagen), Juliane Bernholz(AM–Pharma (Netherlands)), Kathleen D. Liu(University of California San Francisco Medical Center), Kristine Broglio(Berry & Associates (United States)), Marlies Ostermann(St Thomas' Hospital), Ravindra L. Mehta(University of California San Diego), Patrick Murray(Mater Misericordiae University Hospital), Jacques Arend(AM–Pharma (Netherlands)), Bruno François(Inserm), Jan E. Carlsen, Christopher J. Doig(Alberta Health Services), Erik van den Berg(AM–Pharma (Netherlands))
Cited by 17
Related Papers
The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)
|JAMA|2016|28.1k
Surviving Sepsis Campaign
|Critical Care Medicine|2013|9.7k
Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock, 2012
|Intensive Care Medicine|2013|7.3k
Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury
|Critical Care|2007|7.1k